Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients

Completed · Phase 2

Conditions studied: Erythemato-telangiectatic Rosacea

In brief

This study will evaluate the safety, tolerability and efficacy of BFH772 after 12 weeks of treatment as compared to an active control and vehicle in patients with erythemato-telangiectatic rosacea.

Key facts

Study ID

NCT01449591

Run by

Novartis Pharmaceuticals

People needed

36

Starts

2011-09-01

Expected to finish

2012-02-01

Last updated by the study team

2021-02-21

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have persistent facial erythema on the cheeks of at least moderate severity.
• Women must not be able to bear children

You may not qualify if…

• Have more than 12 inflammatory lesions on the face
• Previous treatment of facial skin with lasers or electrocauterisation within 2 months prior to entering the study
• Have facial hair that makes it difficult to evaluate rosacea on the face Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Novartis Investigative Site — Hot Springs, Arkansas, United States
• Novartis Investigative Site — Ann Arbor, Michigan, United States
• Novartis Investigative Site — Paramus, New Jersey, United States
• Novartis Investigative Site — Portland, Oregon, United States
• Novartis Investigative Site — Austin, Texas, United States
• Novartis Investigative Site — Spokane, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.